Thromb Haemost 2000; 84(04): 726-727
DOI: 10.1055/s-0037-1614096
Letters to the Editor
Schattauer GmbH

Risk of Myocardial Infarction in Carriers of Mutations in the Hemochromatosis-associated Gene

Maurizio Margaglione
1   From Unita’ di Aterosclerosi e Trombosi
,
Augusto Di Castelnuovo
3   Dipartimento di Medicina Vascolare e Far-macologia, Consorzio “Mario Negri Sud”, Santa Maria Imbaro
,
Angela Totaro
2   Servizio di Genetica Medica, I.R.C.C.S. “Casa Sollievo della Sofferenza”, S. Giovanni Rotondo, Laboratorio “Angela Valenti” dei Fattori Genetici e Ambien-tali di Rischio Trombotico
,
Licia Iacoviello
3   Dipartimento di Medicina Vascolare e Far-macologia, Consorzio “Mario Negri Sud”, Santa Maria Imbaro
,
Giovanni Di Minno
4   Istituto di Medicina Interna e Geriatria, Universita di Palermo, Italy
› Author Affiliations
Further Information

Publication History

Received 03 May 2000

Accepted after resubmission 17 May 2000

Publication Date:
11 December 2017 (online)

 

 
  • References

  • 1 Tuomainen T-P, Punnonen K, Nyyssönen K, Salonen JT. Association between body iron stores and the risk of acute myocardial infarction in men. Circulation 1998; 97: 1461-6.
  • 2 Edwards CQ, Griffen LM, Goldgar D, Drummond C, Skolnick MH, Kushner JP. Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med 1988; 318: 1355-62.
  • 3 Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, Dormishian D, Domingo Jr R, Ellis MC, Fullan A, Hinton LM. A novel MCH class I-Like gene is mutated in patients with hereditary hemochromatosis. Nat Genet 1996; 13: 399-408.
  • 4 Tuomainen T-P, Kontula K, Nyyssönen K, Lakka TA, Heliö T, Salonen JT. Increased risk of acute myocardial infarction in carriers of the hemochromatosis gene Cys282Tyr mutation: a prospective cohort study in men in the eastern Finland. Circulation 1999; 100: 1274-9.
  • 5 Roest M, van der Schouw YT, de Valk B, Marx JJ, Tempelman MJ, de Groot PG, Sixma JJ, Banga JD. Heterozygosity for a hereditary hemochromatosis gene is associated with cardiovascular death in women. Circulation 1999; 100: 1268-73.
  • 6 Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction. Lancet 1990; 336: 65-71.
  • 7 Carella M, D’Ambrosio L, Totaro A, Grifa A, Valentino MA, Piperno A, Girelli D, Roetto A, Franco B, Gasparini P, Camaschella A. Mutation analysis of the HLA-H gene in Italian hemochromatosis patients. Am J Hum Genet 1997; 60: 828-32.
  • 8 Franco RP, Zago MA, Trip MD, ten Cate D, van den Ende A, Prins MH, Kastelein JJ, Reitsma PH. Prevalence of hereditary hemochromatosis in premature atherosclerotic vascular disease. Br J Hematol 1998; 102: 1172-5.
  • 9 Morrison HI, Semenciw RM, Mao Y, Wigle DT. Serum iron and risk of fatal acute myocardial infarction. Epidemiology 1994; 05: 243-6.
  • 10 Magnusson MK, Sigfusson N, Sigvaldason H, Johannesson GM, Magnus-son S, Thorgeirsson G. Low iron-binding capacity as a risk factor for myocardial infarction. Circulation 1994; 89: 102-8.
  • 11 Baer DM, Tekawa IS, Hurley LB. Iron stores are not associated with acute myocardial infarction. Circulation 1994; 89: 2915-8.
  • 12 Sempos CT, Looker AC, Gillum RF, Makuc DM. Body iron stores and risk of coronary heart disease. N Engl J Med 1994; 330: 1119-24.
  • 13 Bulaj ZJ, Griffen LM, Jorde LB, Edwards CQ, Kushner JP. Clinical and biochemical abnormalities in people heterozygous for hemochromatosis. N Engl J Med 1996; 335: 1799-805.